President, Dongbang Future Tech & Life CO., LTD
Dr. Hunsuk Chung received his Ph.D. in Chemistry from Imperial College London, worked as a researcher at Pfizer in the UK, and is currently CEO of DongbangFTL, an API development company in the Republic of Korea. Recently, it was selected as a COVID-19 treatment manufacturer by the Medicines Patent Pool, a United Nations-backed public health organisation to support low- and middle-income countries with life-saving medicines.
He runs various open Innovation programs such as small molecule-based innovative new drug development (as a type of joint venture) and natural active ingredient development (as the founder of GapiBio). In addition to Korea, he is collaborating with leading universities and professors in the UK, such as Imperial College, Durham, and Reading.
In 2022, he was awarded the Presidential Citation of the Republic of Korea for his contribution to the chemical industry.